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Abstract
There are two main blood-ocular barriers, the blood-aqueous barrier and 
the blood-retinal barrier. The blood-aqueous barrier is formed by the non-
pigmented ciliary epithelium of the ciliary body and the vascular endothelium 
of the iris vessels. The blood-retinal barrier is formed by the vascular 
endothelium of the retinal vessels and the retinal pigment epithelium. 
Four methods of examination are currently used to study the function of 
blood-ocular barriers. Among these, laser flare-cell photometry is a non-
invasive, quantitative method to evaluate the permeability of the blood-
aqueous barrier. Vitreous fluorophotometry is an excellent technique to 
quantitate blood-retinal barrier function. Fluorescein angiography and 
optical coherence tomography are excellent qualitative imaging techniques 
to evaluate blood-retinal barrier function. Current basic research shows 
prostaglandin E2 and other mediators may produce breakdown of the 
blood-aqueous barrier, and vascular endothelial growth factor plays an 
important role in the breakdown of the blood-retinal barrier. Retinal laser 
photocoagulation can induce breakdown of both the blood-aqueous and 
blood-retinal barriers in pigmented rabbits. The four methods of examination 
described herein are excellent measures for clinical application to evaluate 
blood-ocular barrier function in various ocular diseases, many of which 
are discussed here. [Tzu Chi Med J 2008;20(1):25–34]
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1. Introduction
The normal adult eye is approximately spherical in 
shape, with an anteroposterior diameter averaging 
24.2 mm along the geometrical axis. The eye is com-
posed of a three-layered eye wall and an interior por-
tion. The eye wall consists of an outer fibrous layer 
(including the cornea and sclera); a middle vascular 
layer (including the iris, ciliary body and choroid); 
and an inner nerve tissue layer (the retina). The ocular 
vasculature includes the central retinal artery, which 
supplies the retina, and ciliary vessels, which supply 
the outer and middle layers of the eye wall.
The interior portion of the eye is composed of the 
aqueous, lens and vitreous. The aqueous is a clear 
fluid that fills the anterior and posterior chambers 
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of the eye. Aqueous is produced by the ciliary body 
and is secreted into the posterior chamber. It passes 
through the pupil into the anterior chamber, and then 
spreads peripherally toward the angle of the anterior 
chamber. The vitreous is a transparent, avascular, 
inert gel that comprises two-thirds of the eye. It is 99% 
water, with the remaining 1% made up of collagen 
and hyaluronic acid.
The barrier system separates the interior portion 
of the eye from blood entering the eye, and main-
tains the transparency and function of the interior 
portion of the eye. There are two main blood-ocular 
barriers, the blood-aqueous barrier and the blood-
retinal barrier [1].
2. Anatomy and physiology
2.1. The blood-aqueous barrier
There are two main structures involved in the formation 
of the blood-aqueous barrier (BAB), the ciliary body 
and the iris (Fig. 1). The nonpigmented ciliary epi-
thelium of the ciliary body produces the aqueous (the 
fluid in the anterior and posterior chambers). The 
components of the aqueous are quite different from 
those plasma exudates present in the ciliary body 
stroma. There are different concentrations of elec-
trolytes, other small molecules, and a restricted set 
of proteins in low concentrations between the aque-
ous and the plasma. A barrier to the free diffusion 
of molecules is formed by tight junctions between 
the nonpigmented ciliary epithelial cells. This type of 
barrier is an epithelial barrier. In the iris, tight junc-
tions between the vascular endothelial cells contain 
proteins similar to the epithelial tight junctions. This 
type of barrier in the iris vessels is also an endothelial 
barrier [2].
The BAB contributes to the nutrition and function of 
the cornea and the lens. Alterations in the BAB may 
occur in ocular inflammation, intraocular surgery, 
trauma, or vascular diseases. The aqueous becomes 
cloudy due to leakage of plasma proteins into the 
posterior and anterior chambers. The aqueous may 
become plasmoid due to the presence of fibrinogen 
and other proteins. Inflammatory cells may also be 
present when breakdown of the BAB occurs.
2.2. The blood-retinal barrier
The retina has two areas of direct interaction with the 
blood, one at the level of the retinal vessels and the 
other at the level of the choroid-retinal pigment epi-
thelial interface. Thus, two structures comprise the 
blood-retinal barrier (BRB). The BRB is formed by tight 
junctions between the endothelial cells of the retinal 
vessels (the inner BRB) and by similar tight junctions 
in the retinal pigment epithelium (the outer BRB). The 
inner BRB makes the retinal vessels impermeable to 
molecules larger than 20–30 kDa. Small molecules, 
such as glucose and ascorbate, are transported by 
facilitated diffusion. In the outer BRB, the retinal 
pigment epithelial cells are aligned by tight inter-
cellular junctional complexes termed zonula occlu-
dens. Bidirectional transport may occur with various 
metabolites such as glucose. The bulk flow of fluid 
from the retinal side to the choriocapillaries is car-
ried out through mechanisms such as the Na+/K+ 
ATPase pump and by transport of nonionic solutes 
such as amino acids and glucose.
In conclusion, there are two types of molecular 
movement across the BRB. Active transport takes 
place across the BRB, mostly from the vitreous into 
the blood. It has been shown to occur with amino 
acids, a variety of organic anions, prostaglandins, 
and fluorescein. Passive transfer across the BRB and 
into the vitreous due to the concentration gradient 
is extremely limited, but does occur with sodium, 
phosphate, glucose and potassium [3].
3. Methods of examination
3.1. Laser flare-cell photometry
The laser flare-cell meter is a new, noninvasive 
instrument that can be used to quantitatively evalu-
ate the permeability of the BAB by measuring the 
protein concentration and number of cells in the 
anterior chamber. The instrument is composed of 
a He-Ne laser beam system (25 µW intensity, 20 µm 
diameter), a photomultiplier mounted on a slit-lamp 
microscope, and a personal computer which controls 
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Fig. 1 — Anatomy of blood-ocular barriers. The blood-
aqueous barrier is formed by the vascular endothelium of 
the iris vessels and the nonpigmented ciliary epithelium 
of the ciliary body. The blood-retinal barrier is formed by 
the vascular endothelium of the retinal vessels and the 
retinal pigment epithelium.
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the system and analyzes the data detected by the 
photomultiplier. A coaxial halogen illumination light 
is used for observation, but it is turned off during 
measurement by means of a synchronized lens shut-
ter. In practice, the He-Ne laser beam is projected 
into the center of the anterior chamber of the eye by 
means of an optical scanner. The laser light scattered 
by protein and the light reflection from the cells in 
the anterior chamber is passed through a sampling 
window (0.3 × 0.5 mm) in the microscope. The intensity 
of the scattered light collected through the sampling 
window is detected by the photomultiplier, and then 
the data are analyzed by the personal computer (Fig. 
2A) [4,5].
The instrument has two measurement modes, 
one for protein concentration and the other for cell 
counts (Fig. 2B).
3.1.1. Protein concentration measurement mode
The laser beam is scanned vertically for 0.6 mm 
which covers the sampling window. The intensity 
of the light scattered by proteins in the anterior 
chamber is detected by the photomultiplier when 
the laser beam is passed through the sampling win-
dow. Measurements are also taken when the laser 
beam passes above and below the sampling window 
to detect the background signal. The average of the 
background measurements is subtracted from the 
data obtained in the scanned sampling window to 
provide protein measurements. The aqueous flare, 
representing protein in the aqueous, is expressed in 
photon count/msec.
3.1.2. Cell count mode
The laser beam in a Kowa FC-1000 laser flare-cell 
meter (Kowa, Tokyo, Japan) is scanned through a vol-
ume of aqueous of 0.5 × 0.6 × 0.25 mm (0.075 mm3) 
over 0.5 seconds through the sampling window. 
The recently developed FC-2000 scans a volume of 
0.5 mm3 for 0.7 seconds. A strong peak of reflected 
light is obtained when the laser beam strikes a cell 
in the aqueous, and the number of peaks is counted 
by the computer. The peaks in the scattered light are 
counted as the number of cells in the aqueous.
3.2. Vitreous fluorophotometry
Vitreous fluorophotometry is an excellent technique 
to quantitate BRB function. Basically, within 60 min-
utes after intravenous injection of sodium fluorescein, 
fluorophotometry is performed to measure the con-
centration of free fluorescein in the vitreous and in 
the plasma. The simplest measurement of the degree 
of BRB function is the fluorescein concentration 
3 mm from the retina 60 minutes after fluorescein 
administration. A more detailed measurement is esti-
mation of the BRB permeability, which also requires 
estimation of the decay of the plasma fluorescein 
concentration. By comparing the concentrations of free 
fluorescein in these two compartments, the penetra-
tion ratio of the BRB is determined [6–8].
After administration, fluorescein diffuses into the 
vitreous of the normal eye from two routes, anteriorly, 
from the ciliary body and iris vessels, and posteriorly, 
from the retinal and choroidal vessels through the 
BRB. In a normal eye with an intact BRB, permeability 
to fluorescein is limited. In contrast, breakdown of 
the BRB increases BRB permeability, allowing fluo-
rescein to diffuse into the vitreous at a much faster 
rate and in larger amounts.
The Fluorotron Master (Coherent Inc., Palo Alto, CA, 
USA) is the standard instrument for vitreous fluoro-
photometry. This instrument is basically an optical 
fluorophotometer composed of an optoelectronic unit 
and computerized system for data acquisition and 
processing (Fig. 3A). The excitation of fluorescein is 
induced by a conventional halogen lamp filtered to 
match the excitation spectrum of free fluorescein. 
Fluorescein emission is detected by a photomultiplier 
A B
Fig. 2 — Laser flare-cell meter: (A) equipment; (B) recorded data.
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equipped with a barrier filter. The photomultiplier 
then converts the light counts into electronic circuit 
counts. Scans are obtained before and after injec-
tion of fluorescein, and are displayed on a screen 
in concentration units versus distance from the retina 
(Fig. 3B) [6–8].
Vitreous fluorophotometry is performed accord-
ing to the recommended protocol of the reference 
Manual of Ocular Fluorometry published by EUROEYE, 
a concerted action for standardization of ocular 
fluorometry. Briefly, 20% sodium fluorescein is 
first injected intravenously at a dose of 14 mg/kg. 
Fluorophotometric scans are performed along the 
optical axis from the retina to the cornea using the 
posterior segment program on both eyes. These scans 
are taken before fluorescein injection, 3–5 minutes 
after injection, and 60 minutes after injection. Blood 
samples taken from the non-injected arm at 10, 30 
and 50 minutes are placed into tubes containing 
EDTA and subsequently centrifuged at 3000 rpm for 
15 minutes. The plasma is then ultrafiltered using 
Amicon hydrophilic anisotropic membranes. A fluoro-
photometric scan is then performed on the diluted 
ultrafiltrates, measuring the concentration of free 
fluorescein with an optimized protocol to measure 
the BRB penetration ratio.
The penetration ratio of fluorescein into the vitre-
ous is measured according to the following formula:
PR = PV3 mm/Plasma fluorescein integral(3 min–60 min) in 
which PR represents the penetration ratio, and PV3 mm 
represents the average value determined 3 mm in front 
of the choroid retinal peak. The plasma fluorescein 
integral is calculated by standard software.
3.3. Fluorescein angiography
Fluorescein angiography is a qualitative imaging 
technique to evaluate BRB function using a fundus 
camera to photograph the passage of fluorescein in 
the retinal and choroidal circulation after intravenous 
injection. Sodium fluorescein absorbs blue light 
(465–490 nm) and emits green light (520–530 nm). 
However, when sodium fluorescein is injected intra-
venously, about 80–90% of the dye is bound to 
plasma protein and is not available for fluorescence. 
Only the remaining unbound or free fluorescein is 
available to contribute to fluorescence during the 
procedure.
A fundus camera equipped with both excitation 
and barrier filters is used to perform fluorescein 
angiography. A blue excitation filter is placed in front 
of the light beam of the fundus camera, allowing 
only blue light to enter the eye. The free fluorescein 
molecules in the ocular blood vessels are struck by 
the blue light, absorb it, and then emit green light. 
The emitted green light passes through the green 
barrier filter, and is captured on film in the fundus 
camera [9,10].
In fluorescein angiography, the pupils are first 
dilated with topical 1% tropicamide and 10% phenyle-
phrine solution. The patient is seated in front of the 
fundus camera. Initially, color fundus photographs are 
taken. Fluorescein solution is then quickly injected 
intravenously after inserting both the blue excita-
tion and green barrier filters into the fundus camera. 
Photographs are then taken at intervals.
In the normal fluorescein angiogram, the fluores-
cein dye first appears in the choroid via the posterior 
ciliary arteries about 10–15 seconds after intrave-
nous injection into the antecubital vein. Within the 
next 1–3 seconds, the dye appears in the retina via 
the central retinal artery. The dye then flows into the 
retinal arterioles, the capillaries, the retinal veins, and 
finally drains via the central retinal vein (Fig. 4A). 
A fluorescein angiogram might show fluorescein dye 
leakage from abnormal retinal vessels and new ves-
sels, indicating breakdown of the BRB (Fig. 4B).
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Fig. 3 — Vitreous fluorophotometry: (A) equipment; (B) normal scan.
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3.4. Optical coherence tomography
Optical coherence tomography is a high-resolution, 
noninvasive imaging technique that can provide cross-
sectional images of the retina. An interferometer detects 
echo time delays of light reflected from different lay-
ers of the retina and forms an optical cross-section 
of the retina (Figs. 5A and 5B). The optical beam is 
infrared light at 843 nm with a power of approxi-
mately 200 µW, which is well tolerated by the eye. 
The cross-sectional images have a 10-µm depth reso-
lution in the retina. This technique can also be used 
to examine the optic disc, the peripapillary region, 
and the nerve fiber layer [11,12]. Optical coherence 
A B
Fig. 4 — Fluorescein angiography: (A) normal fluorescein angiogram; (B) fluorescein dye leakage from retinal new 
vessels, indicating breakdown of the blood-retinal barrier.
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Fig. 5 — Optical coherence tomography: (A) equipment; (B) normal retina; (C) retinal edema in diabetic retinopathy, 
indicating breakdown of the inner blood-retinal barrier; (D) retinal edema in central serous chorioretinopathy mani-
fested by serous detachment of the neurosensory retina and retinal pigment epithelium, indicating breakdown of the 
outer blood-retinal barrier.
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tomography can also be used to detect retinal edema 
that originates from breakdown of the inner or outer 
BRB (Figs. 5C and 5D).
4. Basic research
Many basic studies have investigated morphologi-
cal changes in the blood-ocular barriers. However, 
recent studies have focused on functional changes.
4.1. Mediators that influence function of 
blood-ocular barriers
The sites of breakdown of the BAB remain unknown, 
but are possibly the stroma of the iris root and 
the iris vessels [13]. Changes may be mediated by 
increased prostaglandin and lactate dehydrogenase 
levels [14,15], and may also be influenced by neuro-
genic or humoral factors [16].
The actions of prostaglandins include miosis, 
vasodilatation, pressure elevation, and increased 
permeability of the BAB. Previous reports suggested 
that dysfunction of the BAB may be minimized or 
eliminated by pre-treatment with a prostaglandin 
inhibitor, such as aspirin or indomethacin [14,15]. 
In studies of prostaglandin E2-induced aqueous flare 
elevation, calcium channel blockers and cyclooxygen-
ase inhibitors partly inhibited aqueous flare eleva-
tion due to their anti-inflammatory activity [17,18].
Intravitreal injection of interleukin (IL)-1 or IL-6 has 
been shown to induce a significant increase in aque-
ous flare values [19]. Among these, intravitreal injec-
tion of IL-1β has been noted to significantly increase 
the release of prostaglandin E2 into the aqueous in 
rabbits [20,21]. Furthermore, IL-1 is induced by IL-6 
in retinal pigment epithelial cells [22].
Vascular endothelial growth factor, which is also 
known as vascular permeability factor, is a specific 
growth factor for endothelial cells [23]. Murata et 
al demonstrated that vascular endothelial growth 
factor plays a role in the breakdown of the BRB in 
streptozotocin-induced diabetic rats [24].
4.2. Effects of retinal laser photocoagulation 
on blood-ocular barriers
Retinal laser photocoagulation has been widely used 
in the treatment of various retinal diseases. Peyman 
and coworkers demonstrated that in the acute stage 
of photocoagulation burns, the BRB is disrupted at 
the level of the retinal pigment epithelium [25].
Vitreous fluorophotometry studies of the effects 
of argon laser retinal photocoagulation and cryother-
apy on the BRB in pigmented rabbits demonstrated 
that both modalities cause a significant breakdown 
in the BRB, which peaks 6 days after treatment; the 
barrier function returns to baseline values by 15 
days post-treatment [26]. Inoue et al reported a sig-
nificant increase in aqueous flare values on the first 
postoperative day following retinal photocoagulation, 
with the values returning to baseline by day 7 [19]. 
A study by our laboratory demonstrated significant 
disruption of the BAB 1 week after retinal laser pho-
tocoagulation. The aqueous flare value peaked on 
day 1, gradually decreased during the first week, and 
became insignificant by day 14 [27].
4.3. Intravitreal administration of 
anti-vascular endothelial 
growth factor agents
The role of vascular endothelial growth factor in many 
ocular diseases in which breakdown of the blood-
ocular barriers and angiogenesis play major roles 
has been identified. These include diabetic retinopa-
thy, age-related macular degeneration, retinal vein 
occlusion, and other diseases [28,29]. Inhibition of 
vascular endothelial growth factor activity by either 
pegaptanib (Macugen; Eyetech Pharmaceuticals 
Inc., New York, NY, USA) or intravitreal ranibizumab 
(Lucentis; Genentech Inc., South San Francisco, CA, 
USA) has been shown to be effective in the treatment 
of age-related macular degeneration [30,31].
Recently, there have been encouraging reports 
about off-label use of intravitreal bevacizumab 
(Avastin; Genentech Inc.) in the treatment of many 
ocular diseases. Bevacizumab is a full-length human-
ized murine monoclonal IgG antibody that binds to 
all isoforms of the vascular endothelial growth factor 
molecule [32,33]. However, intravitreal injection of 
a full length IgG antibody has the potential risk of 
an intraocular inflammatory response, and a recent 
study by our laboratory demonstrated that intravit-
real injection of bevacizumab can produce break-
down of the BAB in rabbits.
5. Clinical applications
Many ocular diseases alter the function of the blood-
ocular barriers. Some common ocular diseases 
involving blood-ocular barriers, or disease treatments 
that affect blood-ocular barriers, are described.
5.1. Medications
Some topical and systemic medications affect 
BAB function [34]. Medications that increase the 
aqueous flare intensity include pilocarpine [35], 
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beta-blockers [36], acetazolamide [37], mannitol [38] 
and apraclonidine [39]. Topical application of the 
mydriatics tropicamide and phenylephrine results in 
a decrease in aqueous flare intensity. The magnitude 
of this change is approximately 10–20% in healthy 
subjects [34].
5.2. Diabetic retinopathy
In recent decades, the number of individuals with 
diabetes has increased. In surveys performed in 
1970, 1979 and 1986 in Taipei, the prevalence of 
diabetes was 5.05%, 7.10% and 8.17%, respectively. 
In rural areas of Taiwan, a prevalence of 5.06% was 
noted during a 1986 survey [40–42]. Diabetic retinop-
athy has now become a major cause of loss of visual 
acuity in adults [43].
Diabetic retinopathy is generally associated with 
increased permeability of the blood-ocular barrier. 
Laser flare photometry demonstrated that abnor-
mality of BAB function is correlated with the clinical 
grade of retinopathy. There was no significant differ-
ence between healthy subjects and diabetic subjects 
without retinopathy [44,45].
In some patients, vitreous fluorophotometry shows 
abnormality in BRB function before ophthalmoscopy 
can detect any abnormalities [6]. Abnormalities in 
BRB function in diabetic subjects may be reversed 
with strict metabolic control [46]. Some reports dem-
onstrated that the vitreous fluorophotometric value 
is normal in diabetic subjects with no or minimal 
retinopathy, and is significantly higher in advanced 
retinopathy [47,48].
In Fig. 4B, fluorescein angiography shows marked 
fluorescein dye leakage from the optic disc and retinal 
new vessels in a patient with proliferative diabetic 
retinopathy. In Fig. 5C, optical coherence tomography 
shows cystoid spaces in the retina in a patient with 
diabetic retinopathy. These features demonstrate 
that this disease mainly affects the inner BRB.
5.3. Retinitis pigmentosa and degenerative 
diseases
Retinitis pigmentosa is a group of hereditary diseases 
with a primary abnormality of the photoreceptor-retinal 
pigment epithelium complex. It is characterized by 
night blindness, loss of peripheral vision, retinal 
bone-spicule pigmentation, retinal arteriolar attenu-
ation, and waxy optic disc pallor. Patients with retinitis 
pigmentosa have been shown to have abnormal BAB 
function, as indicated by increased aqueous flare 
intensity. In addition, subjects with typical retini-
tis pigmentosa have higher aqueous flare intensity 
than those with pericentral retinitis pigmentosa [49]. 
Patients with retinitis pigmentosa have also been 
shown to have abnormal BRB function, as assessed 
by vitreous fluorophotometry. Abnormal vitreous 
fluorophotometric recordings may precede ophthal-
mologically visible fundus changes [50].
Abnormal BAB function has also been detected 
with other retinal degenerative diseases, including 
crystalline retinopathy [51], retinitis punctata albecens 
[52], and reticular dystrophy of the retinal pigment 
epithelium [53]. Among these, crystalline retinopathy 
also has associated abnormal BRB function [54].
5.4. Age-related macular degeneration
Age-related macular degeneration is a common degen-
erative condition of the retina that may affect the 
central vision. It is divided into non-exudative and 
exudative types. Exudative age-related macular degen-
eration is characterized by the presence of choroidal 
neovascularization, which may lead to hemorrhage 
or lipid exudation.
Laser flare photometry has been used to examine 
various stages of age-related macular degeneration. 
The aqueous flare values increase with advancing 
age-related macular degeneration in both the non-
exudative and exudative types [55]. Vitreous fluor-
ophotometry has demonstrated alteration in BRB 
function [56]. Fluorescein angiography shows fluo-
rescein dye leakage from the choroidal neovascular 
vessels. Optical coherence tomography shows fusiform 
thickening in the reflective band, consistent with a 
neovascular membrane.
5.5. Ocular tumors
Malignant melanoma of the ciliary body or choroid 
may cause alterations in blood-ocular barriers. Laser 
flare photometry demonstrated that the aqueous flare 
values were higher in eyes with malignant melanoma 
than in normal controls. The researchers described 
the ability of laser flare photometry to differentiate 
melanoma from benign lesions with an exudative 
component [57]. Another report demonstrated that 
aqueous flare values are related to tumor height and 
volume [58]. A study by our laboratory demonstrated 
that combined hamartoma of the retina and retinal 
pigment epithelium might cause a breakdown in BAB 
function [59].
5.6. Ocular inflammation
Laser flare photometry has been widely used to 
study BAB function in various types of uveitis. This 
method could be used to monitor the severity of 
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uveitis, to predict recurrence, and to monitor the 
effects of treatment. Increased aqueous flare values 
have been reported in patients with Behcet’s disease 
[60], sarcoidosis [60], ocular toxoplasmosis [61], 
acute anterior uveitis [61], herpes zoster ophthalmi-
cus [61], acquired immunodeficiency syndrome [62], 
and cytomegalovirus retinitis [62].
Laser flare photometry has also been applied to 
study levels of post-surgical inflammation of the eye. 
Aqueous flare values have been reported to increase 
after cataract surgery [63]. Anti-inflammatory effects 
of diclofenac and fluorometholone on BAB func-
tion after cataract surgery have been reported [64]. 
Alteration in BAB function has also been noted after 
retinal detachment surgery [65].
5.7. Central serous chorioretinopathy
Central serous chorioretinopathy is characterized by 
a circumscribed serous detachment of the neuro-
sensory retina in the macula. An associated serous 
detachment of the retinal pigment epithelium may 
occur. Vitreous fluorophotometry has demonstrated 
abnormal BRB function. Abnormalities in vitreous 
fluorophotometric recordings were associated with 
the size and height of the retinal serous detachment 
and the stage of activity [56].
In unpublished work, our laboratory has used 
laser flare photometry to demonstrate abnormal 
BAB function in the acute stage of retinal serous 
detachment. Fluorescein angiography shows a spot 
of hyperfluorescence at the level of the retinal pigment 
epithelium. There is fluorescein dye pooling in the 
late phase of neurosensory detachment. Optical 
coherence tomography shows serous detachment of 
the neurosensory retina, and may have been associ-
ated with serous detachment of the retinal pigment 
epithelium (Fig. 5D). These features demonstrate 
that this disease mainly affects the outer BRB.
6. Conclusion
Blood-ocular barriers play important roles in the main-
tenance and function of the eye. Abnormal function 
in blood-ocular barriers may occur in various ocu-
lar diseases. Four current methods of examination, 
laser flare-cell photometry, vitreous fluorophotom-
etry, fluorescein angiography and optical coherence 
tomography, provide excellent qualitative and quanti-
tative evaluation of the function of the blood-ocular 
barriers. Further development of new techniques to 
provide more detailed analysis of the function of the 
blood-ocular barriers, and new medications for the 
management of abnormalities of the blood-ocular 
barriers, is encouraging.
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